By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Gulf PressGulf Press
  • Home
  • Gulf News
    • Saudi Arabia
    • UAE24/7
    • Kuwait
    • Qatar
    • Bahrain
    • Oman
  • World
  • Business
    • Market DataLive
    • Finance
    • Economy
    • Energy
    • Crypto
    • ForexHot
    • Tech
  • Sports
  • Lifestyle
  • Videos
Search
Countries
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Bahrain
  • Oman
More Topics
  • Technology
  • Health
  • Entertainment
  • Crypto
  • Forex
  • Stocks
Site Links
  • Business Hub
  • Trending
  • Weather
  • Customize Interests
  • Bookmarks
  • Newsletter
  • Terms
  • Press Release
  • Advertise
  • Contact
© 2023 Gulf Press. All Rights Reserved.
Reading: New medication may be beneficial for treating moderate to severe conditions
Share
Notification Show More
Latest News
Jordan to Host Iraq in the Final Round of the Asian World Cup Qualifiers After Securing Historic Spot
Sports
The Myriad Redefines Student Living for a Mobile, Urban Generation
UAE
L’Oréal Paris Welcomes Yasmine Sabri as New Brand Ambassador for the Middle East
Lifestyle
Roland Garros 2025: A New Era of Viewing, A Tribute to Legends, and Moments to Remember
Sports World
Bitget Celebrates Bitcoin Pizza Day by Distributing Over 5000 Pizzas in Over 20 Cities Worldwide
Crypto
Aa
Gulf PressGulf Press
Aa
  • Gulf News
  • World
  • Business
  • Entertainment
  • Lifestyle
  • Sports
  • Videos
Search
  • Home
    • Videos
    • Business Hub
    • Trending
  • Gulf
    • Saudi Arabia
    • UAE
    • Kuwait
    • Qatar
    • Bahrain
    • Oman
  • Business
    • Market Data
    • Crypto
    • Economy
    • Energy
    • Finance
    • Forex
    • Tech
  • More News
    • World
    • Lifestyle
    • Entertainment
    • Sports
Have an existing account? Sign In
Follow US
  • Terms
  • Press Release
  • Advertise
  • Contact
© 2023 Gulf Press. All Rights Reserved.
Gulf Press > Health > New medication may be beneficial for treating moderate to severe conditions
Health

New medication may be beneficial for treating moderate to severe conditions

News Room
Last updated: 2024/10/01 at 4:19 PM
News Room
Share
4 Min Read
SHARE

Ulcerative colitis, a type of inflammatory bowel disease (IBD), is known for causing unpleasant digestive symptoms such as pain, cramping, and diarrhea. Researchers continue to seek out the most effective medications to treat this condition. Recently, a study found that the medication tulisokibart may help individuals with moderate to severe ulcerative colitis achieve clinical remission. This chronic condition involves inflammation and ulcers in the colon, with ongoing research looking to expand treatment options. Another study published in the New England Journal of Medicine tested an anti-TL1A monoclonal antibody that showed promise in treating ulcerative colitis, with tulisokibart outperforming the placebo in treating moderate to severe active cases.

As noted by study author Bruce E. Sands, MD, MS, there has been progress in developing new agents to treat IBDs, but there is still a need for more effective therapies as less than 50% of patients achieve remission within a year. The medication tulisokibart targets a specific cytokine known as human tumor necrosis factor-like cytokine 1A (TL1A), which is elevated in individuals with IBD. Researchers wanted to determine how well this medication could help those with active moderate to severe ulcerative colitis achieve clinical remission. The study included participants aged 18 or older who had not responded well to certain ulcerative colitis treatments.

The double-blind, placebo-controlled trial had two cohorts, with participants being randomized to receive either intravenous tulisokibart or a placebo at various intervals. Data showed that tulisokibart was superior to the placebo in achieving remission and clinical response. Among participants who tested likely to respond to the medication, the intervention group had a significantly higher rate of achieving clinical remission compared to the placebo group. While the study had limitations such as a small sample size and a relatively short duration, it provides valuable insights into potential treatment options for ulcerative colitis.

Dr. Mejdi Ahmad, a board-certified gastroenterologist, noted that the trial’s findings suggest that tulisokibart may produce beneficial clinical remission in moderate ulcerative colitis patients compared to a placebo. The study paves the way for future targeted therapies that may deliver therapeutic results similar or even surpass the effectiveness of current treatment options. While more research is needed to further evaluate tulisokibart’s therapeutic index and long-term effects, the medication is set to enter a phase 3 program following the successful completion of the phase 2 study for potential FDA approval.

In conclusion, the study on tulisokibart represents a significant advancement in the treatment of ulcerative colitis, offering hope for individuals with moderate to severe forms of the condition. With ongoing research and clinical trials, new medications like tulisokibart may soon become part of the standard treatment regimen for ulcerative colitis patients. By targeting specific cytokines and inflammatory pathways, these innovative therapies have the potential to improve remission rates and overall outcomes in individuals living with this chronic gastrointestinal disorder.

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
I have read and agree to the terms & conditions
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
News Room October 1, 2024
Share this Article
Facebook Twitter Copy Link Print
Previous Article The Impact of People-Pleasing Behavior on Menopause – News
Next Article Conference Highlighting Oman’s Real Estate Developments
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

235.3k Followers Like
69.1k Followers Follow
56.4k Followers Follow
136k Subscribers Subscribe
- Advertisement -
Ad imageAd image

Latest News

Jordan to Host Iraq in the Final Round of the Asian World Cup Qualifiers After Securing Historic Spot
Sports June 10, 2025
The Myriad Redefines Student Living for a Mobile, Urban Generation
UAE May 27, 2025
L’Oréal Paris Welcomes Yasmine Sabri as New Brand Ambassador for the Middle East
Lifestyle May 23, 2025
Roland Garros 2025: A New Era of Viewing, A Tribute to Legends, and Moments to Remember
Sports World May 22, 2025

You Might also Like

Health

Mindfulness could be equally effective as antidepressants

October 17, 2024
Health

What is the impact of caffeine on the risk of developing diseases?

October 17, 2024
Health

Scientists discover combination of 14 genes that enhance outcomes

October 16, 2024
Health

Seizure medication demonstrates potential in individuals with no genetic risk

October 16, 2024
Health

Heart disease increases risk, heparin can postpone onset

October 16, 2024
Health

What type of breakfast is most effective for weight loss in women compared to men?

October 15, 2024
Health

How does the brain remove “waste” to protect itself?

October 14, 2024
Health

How does stress, sleep, and gut imbalances affect it?

October 13, 2024
//

Gulf Press is your one-stop website for the latest news and updates about Arabian Gulf and the world, follow us now to get the news that matters to you.

Quick Link

  • Privacy Policy
  • Terms of ue
  • Advertise
  • Contact

How Topics

  • Gulf News
  • International
  • Business
  • Lifestyle

Sign Up for Our Newsletter

Subscribe to our newsletter to get our latest news instantly!

I have read and agree to the terms & conditions
Gulf PressGulf Press
Follow US

© 2023 Gulf Press. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?